Wall Street brokerages predict that Krystal Biotech Inc (NASDAQ:KRYS) will announce ($0.25) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Krystal Biotech’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.27). Krystal Biotech reported earnings of ($1.26) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 80.2%. The firm is expected to announce its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Krystal Biotech will report full year earnings of ($1.01) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.89). For the next year, analysts anticipate that the firm will post earnings of ($1.46) per share, with EPS estimates ranging from ($2.03) to ($0.96). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Krystal Biotech.
Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.12.
NASDAQ:KRYS opened at $19.86 on Friday. Krystal Biotech has a one year low of $8.03 and a one year high of $24.89. The stock has a market capitalization of $231.88 million and a P/E ratio of -13.42.
In other news, insider Krish S. Krishnan acquired 25,000 shares of the business’s stock in a transaction on Thursday, October 18th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 45.80% of the company’s stock.
Large investors have recently modified their holdings of the business. Acadian Asset Management LLC raised its holdings in shares of Krystal Biotech by 552.2% during the second quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares during the period. BlackRock Inc. raised its holdings in shares of Krystal Biotech by 75.4% during the second quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares during the period. Finally, P.A.W. Capital Corp acquired a new stake in shares of Krystal Biotech during the third quarter worth $527,000. 21.77% of the stock is currently owned by institutional investors.
Krystal Biotech Company Profile
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: How is a Moving Average Calculated?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.